Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Kadmon Holdings Llc (KDMN)

Kadmon Holdings Llc (KDMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting ACCESS Newswire - Fri Oct 1, 2021

NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein,...

KDMN : 9.50 (+0.21%)
Kadmon Announces Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer's 36th Annual Meeting ACCESS Newswire - Fri Oct 1, 2021

NEW YORK, NY / ACCESSWIRE / October 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced it will present data from the ongoing Phase 1 clinical trial of KD033, its anti-PD-L1/IL-15 fusion protein,...

KDMN : 9.50 (+0.21%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates MDLA, MSON, KDMN, ECHO; Shareholders are Encouraged to Contact the Firm ACCESS Newswire - Fri Sep 24, 2021

NEW YORK, NY / ACCESSWIRE / September 24, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Medallia, Inc. (NYSE: MDLA) concerning potential...

MSON : 26.54 (+4.74%)
ECHO : 86.13 (+2.67%)
MDLA : 33.99 (+0.06%)
KDMN : 9.50 (+0.21%)
Sanofi To Acquire Kadmon To Further Strengthen Growth of Transplant Business ACCESS Newswire - Wed Sep 8, 2021

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two...

KDMN : 9.50 (+0.21%)
Kadmon Announces U.S. Availability of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD) ACCESS Newswire - Thu Aug 19, 2021

NEW YORK, NY / ACCESSWIRE / August 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets is now commercially available for shipment...

KDMN : 9.50 (+0.21%)
Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results ACCESS Newswire - Thu Aug 5, 2021

NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021. "The recent...

KDMN : 9.50 (+0.21%)
Kadmon Announces REZUROCK(TM) (belumosudil) Added to National Comprehensive Cancer Network(R) Clinical Practice Guidelines in Oncology for Hematopoietic Cell Transplantation ACCESS Newswire - Wed Aug 4, 2021

NEW YORK, NY / ACCESSWIRE / August 4, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that the National Comprehensive Cancer Network® (NCCN) added REZUROCKTM (belumosudil) tablets to its NCCN...

KDMN : 9.50 (+0.21%)
Kadmon Announces Pivotal Trial Data Published in the Journal Blood for REZUROCK(TM) (Belumosudil) in Chronic Graft-Versus-Host Disease (cGVHD) ACCESS Newswire - Mon Jul 19, 2021

- REZUROCK is approved by the U.S. FDA for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - NEW YORK, NY / ACCESSWIRE...

KDMN : 9.50 (+0.21%)
U.S. FDA Grants Full Approval of REZUROCK(TM) (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD) ACCESS Newswire - Fri Jul 16, 2021

- REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - - Kadmon to Host Conference Call on...

KDMN : 9.50 (+0.21%)
Kadmon to Present at Upcoming Investor Conferences ACCESS Newswire - Tue May 25, 2021

NEW YORK, NY / ACCESSWIRE / May 25, 2021 / Kadmon Holdings, Inc. (Nasdaq:KDMN) today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present at the following virtual...

KDMN : 9.50 (+0.21%)

Barchart Exclusives

Here’s Why Verizon Stock Is a Buy for Income Investors in August Barchart - Thu Jul 30, 6:30PM CDT
A safer dividend, stronger free cash flow, and new growth opportunities make Verizon increasingly attractive for income-focused investors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.